NDAVAGINALCREAM
Approved
Nov 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
SYNTHETIC CONJUGATED ESTROGENS A (estrogens, conjugated synthetic a) by Teva is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. First approved in 2008.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Synthetic Conjugated Estrogens A is a hormone replacement therapy containing a mixture of synthetic estrogens designed to mimic endogenous estrogen activity. Administered as a vaginal cream, it binds to nuclear estrogen receptors to modulate reproductive system function and secondary sexual characteristics. This formulation is indicated for postmenopausal women seeking estrogen replacement therapy.
LOE Approaching
Product approaching loss of exclusivity with limited linked job opportunities, suggesting a consolidating team focused on transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on SYNTHETIC CONJUGATED ESTROGENS A at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.